Taken together, the results suggest that the mechanism of afatinib in sensitive NSCLC cells is by decreasing CIP2A through a reduction in Elk-1 which restores PP2A activity and leads to p-AKT downregulation, thereby inducing cancer-cell apoptosis (Figure 6E). The gene discussed is PTPA; the disease is cancer.